secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001493152-24-046707
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26
--------------------------------------------------------------------------

- Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.
- Trading begins November 26, 2024 at 10:00 a.m. ET under ticker 'KAPA'.
- Dual listing aims to access global investor base outside U.S., unlock liquidity, enhance price discovery.
- CEO John Yu says listing supports shareholder value and advancement of lead drug ENV105 in cancer trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/0001493152-24-046707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer